Beijing 's BeiGene closed on a 42-acre US site in the Princeton , NJ area where it will build a manufacturing center and house clinical R&D operations. The company said it would invest hundreds of millions of dollars to build a state-of-the art 400,000 square feet biologic manufacturing facility. In its first phase, the plant will include up to 16,000 liters of biologics capacity, along with clinical R&D and office space. The site has more than one million square feet of space for additional facilities as needed. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //